Save time and get answers to complex questions with AI chat
How many years does kadcyla's market exclusivity last?Prolia and osteonecrosis?When is the expected fda decision date for apotex's ruxolitinib resubmission?Dabrafenib mesylate when the patent is expiring in india?Guselkumab loss of exclusitivy?
See the DrugPatentWatch profile for alpelisib
I don’t have enough information in your prompt to identify what you mean by “Novartis AG 2009 patent application alpelisib synthesis Byl719.” What I need to answer accurately (pick any one): - The exact patent number (e.g., WO____/EP____/US____) or a link - The publication number (WO/EP/US) or the applicant name as it appears on the document - The relevant claim or section (e.g., “synthesis example,” “intermediate,” “process,” “compound of formula I”) - A DrugPatentWatch.com link to the specific record you’re referring to Once you share one of those, I can tell you: - Whether the 2009 filing is about alpelisib (BYL719) specifically or a related intermediate/synthesis route - Who the inventors/assignee are and what the application covers - The key synthesis/process features described in the publication If you can paste the patent/publication number here, I’ll respond with a precise, citation-backed explanation.
Other Questions About Alpelisib :